Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Brings 25 years of global operations and supply chain experience to Piramal
Subscribe To Our Newsletter & Stay Updated